Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | PFKFB2 | O60825 | 1/20 | 0.40 |
| ▸ | PFKFB1 | P16118 | 1/20 | 0.40 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 4/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236792 | 0.87 | MAPT (0.47) | PFKFB2PFKFB1PFKFB3TP53MCL1 | |
| SCHEMBL19208493 | 0.82 | SMN1; SMN2 (0.45) | SMN1; SMN2PFKFB2PFKFB1PFKFB3GAA | |
| SCHEMBL19236884 | 0.81 | CFD (0.40) | TP53MCL1ELANELMNA | |
| SCHEMBL19236948 | 0.80 | PFKFB2 (0.41) | PFKFB2PFKFB1PFKFB3TP53MAPT | |
| SCHEMBL18555991 | 0.80 | SMN1; SMN2 (0.43) | SMN1; SMN2GAANPSR1ELANEKRAS | |
| SCHEMBL23368304 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2GAANPSR1LMNAKRAS | |
| SCHEMBL19237004 | 0.79 | ELANE (0.39) | PFKFB2PFKFB1PFKFB3TP53ELANE | |
| SCHEMBL15541589 | 0.70 | HTR6 (0.39) | SMN1; SMN2PFKFB2PFKFB1PFKFB3GAA | |
| SCHEMBL15542673 | 0.70 | ELANE (0.39) | SMN1; SMN2PFKFB2PFKFB1PFKFB3ELANE | |
| SCHEMBL26619479 | 0.69 | SMN1; SMN2 (0.41) | SMN1; SMN2GAAELANELMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-07-13 | — | — | US | disclosed |
| EP-3411411-B3 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2022-01-26 | — | — | EP | disclosed |
| EP-3925956-A1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BioCryst Pharmaceuticals, Inc. (US) | 2021-12-22 | — | — | EP | disclosed |
| EP-3411411-B1 | 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS | BIOCRYST PHARM INC (US) | 2021-05-19 | — | — | EP | disclosed |
| WO-2017136395-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | BIOCRYST PHARMACEUTICALS, INC. (US) | 2017-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218578-A1 | BENZOPYRAZOLE COMPOUNDS AND ANALOGUES THEREOF | C9, C5, C1QBP | SMN1; SMN2 2279/4885PFKFB2 1327/4885PFKFB1 1028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.